Last reviewed · How we verify
R-CHOP14 induction regimen
At a glance
| Generic name | R-CHOP14 induction regimen |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma (PHASE2)
- Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-CHOP14 induction regimen CI brief — competitive landscape report
- R-CHOP14 induction regimen updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI